This article contains links to products or services from one or more of our advertisers or partners. We may receive a commission when you click or make a purchase using our site. Learn more about how we make money.

How to buy Outlook Therapeutics stock | $1.15

Own Outlook Therapeutics stock in just a few minutes.

Posted

Fact checked

Outlook Therapeutics, Inc is a biotechnology business based in the US. Outlook Therapeutics shares (OTLK) are listed on the NASDAQ and all prices are listed in US Dollars. Outlook Therapeutics employs 14 staff and has a trailing 12-month revenue of around USD$5.9 million.

How to buy shares in Outlook Therapeutics

  1. Compare share trading platforms. If you're a beginner, look for a platform with low commissions, expert ratings and investment tools to track your portfolio. Narrow down top brands with our comparison table.
  2. Open and fund your brokerage account. Complete an application with your personal and financial details, like your ID and bank information. Fund your account with a bank transfer, credit card or debit card.
  3. Search for Outlook Therapeutics. Find the stock by name or ticker symbol: OTLK. Research its history to confirm it's a solid investment against your financial goals.
  4. Purchase now or later. Buy today with a market order or use a limit order to delay your purchase until Outlook Therapeutics reaches your desired price. To spread out your purchase, look into dollar-cost averaging, which smooths out buying at consistent intervals and amounts.
  5. Decide on how many to buy. At last close price of USD$1.15, weigh your budget against a diversified portfolio that can minimize risk through the market's ups and downs. You may be able to buy a fractional share of Outlook Therapeutics, depending on your broker.
  6. Check in on your investment. Congratulations, you own a part of Outlook Therapeutics. Optimize your portfolio by tracking how your stock — and even the business — performs with an eye on the long term. You may be eligible for dividends and shareholder voting rights on directors and management that can affect your stock.

Outlook Therapeutics share price

Use our graph to track the performance of OTLK stocks over time.

Outlook Therapeutics shares at a glance

Information last updated 2020-12-01.
Latest market close USD$1.15
52-week range USD$0.499 - USD$1.73
50-day moving average USD$0.9328
200-day moving average USD$1.0449
Wall St. target price USD$5.25
PE ratio N/A
Dividend yield N/A (0%)
Earnings per share (TTM) USD$-2.886

Buy Outlook Therapeutics shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.
Name Product Stock trade fee Asset types Option trade fee Annual fee
Vanguard
$0
Stocks, Mutual funds, ETFs, Forex
$1
$20 per year
Get a personal advisor when you open an account with at least $50,000.
Robinhood
$0
Stocks, Options, ETFs, Cryptocurrency
$0
0%
Make unlimited commission-free trades in stocks, funds, and options with Robinhood Financial.
Sofi Invest
$0
Stocks, ETFs, Cryptocurrency
N/A
0%
A free way to invest in stocks, ETFs and crypto.
Interactive Brokers
$0
Stocks, Bonds, Options, Mutual funds, Index funds, ETFs, Futures, Cash
$0 + $0.65/contract, $1 minimum
0%
IBKR Lite offers $0 commissions, and IBKR Pro offers advanced tools for professional traders.
TD Ameritrade
$0
or $25 broker-assisted
Stocks
$0 + $0.65/contract,
or $25 broker-assisted
TD Ameritrade features $0 commission for online stock, but watch out for high short-term ETF and broker-assisted trading fees.
Moomoo
$0 for US stocks
Stocks, Options, ETFs
$0
Trade stocks on the US, Hong Kong, Shanghai and Shenzhen markets.
loading

Compare up to 4 providers

The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.

Is it a good time to buy Outlook Therapeutics stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Outlook Therapeutics price performance over time

Historical closes compared with the close of $1.15 from 2020-11-16

1 week (2020-11-25) -4.96%
1 month (2020-11-06) 40.24%
3 months (2020-09-04) 76.92%
6 months (2020-06-05) -3.36%
1 year (2019-12-06) 3.60%
2 years (2018-12-06) 88.52%
3 years (2017-12-06) -19.01%
5 years (2015-12-02) N/A

Outlook Therapeutics financials

Revenue TTM USD$5.9 million
Gross profit TTM USD$-15,659,128
Return on assets TTM -60.44%
Return on equity TTM -737.24%
Profit margin 0%
Book value $0.087
Market capitalisation USD$152.6 million

TTM: trailing 12 months

Shorting Outlook Therapeutics shares

There are currently 2.8 million Outlook Therapeutics shares held short by investors – that's known as Outlook Therapeutics's "short interest". This figure is 13.9% down from 3.2 million last month.

There are a few different ways that this level of interest in shorting Outlook Therapeutics shares can be evaluated.

Outlook Therapeutics's "short interest ratio" (SIR)

Outlook Therapeutics's "short interest ratio" (SIR) is the quantity of Outlook Therapeutics shares currently shorted divided by the average quantity of Outlook Therapeutics shares traded daily (recently around 824376.85459941). Outlook Therapeutics's SIR currently stands at 3.37. In other words for every 100,000 Outlook Therapeutics shares traded daily on the market, roughly 3370 shares are currently held short.

However Outlook Therapeutics's short interest can also be evaluated against the total number of Outlook Therapeutics shares, or, against the total number of tradable Outlook Therapeutics shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Outlook Therapeutics's short interest could be expressed as 0.02% of the outstanding shares (for every 100,000 Outlook Therapeutics shares in existence, roughly 20 shares are currently held short) or 0.0263% of the tradable shares (for every 100,000 tradable Outlook Therapeutics shares, roughly 26 shares are currently held short).

Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Outlook Therapeutics.

Find out more about how you can short Outlook Therapeutics stock.

Outlook Therapeutics share dividends

We're not expecting Outlook Therapeutics to pay a dividend over the next 12 months.

Have Outlook Therapeutics's shares ever split?

Outlook Therapeutics's shares were split on a 1:8 basis on 18 March 2019. So if you had owned 8 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Outlook Therapeutics shares – just the quantity. However, indirectly, the new 700% higher share price could have impacted the market appetite for Outlook Therapeutics shares which in turn could have impacted Outlook Therapeutics's share price.

Outlook Therapeutics share price volatility

Over the last 12 months, Outlook Therapeutics's shares have ranged in value from as little as $0.499 up to $1.73. A popular way to gauge a stock's volatility is its "beta".

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Outlook Therapeutics's is -0.0639. This would suggest that Outlook Therapeutics's shares have been inversely-correlated to the average (for this exchange) – so when the broader market trended up or down, Outlook Therapeutics has bucked the trend.

Outlook Therapeutics overview

Outlook Therapeutics, Inc., a late clinical-stage biopharmaceutical company, focuses on developing and commercializing monoclonal antibodies for various ophthalmic indications. Its lead product candidate is ONS-5010, a proprietary ophthalmic formulation of bevacizumab product candidate that is in Phase-III clinical trial for the treatment of wet age related macular degeneration and other retina diseases. Outlook Therapeutics, Inc. has collaboration and license agreements with MTTR, LLC; IPCA Laboratories Limited; Laboratorios Liomont, S.A. de C.V.; BioLexis Pte. Ltd.; and Zhejiang Huahai Pharmaceutical Co., Ltd. The company was formerly known as Oncobiologics, Inc. and changed its name to Outlook Therapeutics, Inc. in November 2018. Outlook Therapeutics, Inc. was founded in 2010 and is headquartered in Cranbury, New Jersey.

Frequently asked questions

More guides on Finder

Ask an Expert

You are about to post a question on finder.com:

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • finder.com is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked

Finder.com provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and finder.com Terms of Use.

Questions and responses on finder.com are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site